Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia.
作者信息
Farrell Martilias, Roth Bryan L
机构信息
Division of Medicinal Chemistry, Department of Pharmacology, NIMH Psychoactive Drug Screening Program, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC 27759, USA.
出版信息
Neuropsychopharmacology. 2010 Mar;35(4):851-2. doi: 10.1038/npp.2009.206.
Abstract
摘要
相似文献
1
Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia.
Neuropsychopharmacology. 2010 Mar;35(4):851-2. doi: 10.1038/npp.2009.206.
2
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83. doi: 10.1073/pnas.0800567105. Epub 2008 Aug 4.
3
Positive allosteric modulation of M and M muscarinic receptors as potential therapeutic treatments for schizophrenia.
Neuropharmacology. 2018 Jul 1;136(Pt C):438-448. doi: 10.1016/j.neuropharm.2017.09.012. Epub 2017 Sep 9.
4
Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
Neuropsychopharmacology. 2010 Mar;35(4):855-69. doi: 10.1038/npp.2009.194. Epub 2009 Nov 25.
5
Activation of the mGlu metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M muscarinic receptor allosteric modulators.
Mol Psychiatry. 2020 Nov;25(11):2786-2799. doi: 10.1038/s41380-018-0206-2. Epub 2018 Aug 16.
6
M/M receptors as potential therapeutic treatments for schizophrenia: A comprehensive study.
Bioorg Med Chem. 2024 May 1;105:117728. doi: 10.1016/j.bmc.2024.117728. Epub 2024 Apr 16.
7
Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.
Neuron. 2017 May 3;94(3):431-446. doi: 10.1016/j.neuron.2017.03.016.
8
Mutual activation of glutamatergic mGlu and muscarinic M receptors reverses schizophrenia-related changes in rodents.
Psychopharmacology (Berl). 2018 Oct;235(10):2897-2913. doi: 10.1007/s00213-018-4980-y. Epub 2018 Jul 27.
9
Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M Muscarinic Acetylcholine Receptor.
J Med Chem. 2024 Jul 11;67(13):10831-10847. doi: 10.1021/acs.jmedchem.4c00293. Epub 2024 Jun 18.
10
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M PAM VU0467154.
Neuropharmacology. 2018 Jan;128:492-502. doi: 10.1016/j.neuropharm.2017.07.013. Epub 2017 Jul 17.
引用本文的文献
1
Discovery of Pre-Clinical Candidate /: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy.
ACS Chem Neurosci. 2025 Jun 4;16(11):2141-2162. doi: 10.1021/acschemneuro.5c00277. Epub 2025 May 26.
2
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM).
ACS Chem Neurosci. 2024 Sep 24;15(20):3744-54. doi: 10.1021/acschemneuro.4c00465.
3
Discovery of VU6008677: A Structurally Distinct Tricyclic M Positive Allosteric Modulator with Improved CYP450 Profile.
ACS Med Chem Lett. 2024 Jul 3;15(8):1358-1366. doi: 10.1021/acsmedchemlett.4c00249. eCollection 2024 Aug 8.
4
Discovery of structurally distinct tricyclic M positive allosteric modulator (PAM) chemotypes - Part 2.
Bioorg Med Chem Lett. 2021 Dec 1;53:128416. doi: 10.1016/j.bmcl.2021.128416. Epub 2021 Oct 26.
5
Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease.
Molecules. 2018 Dec 7;23(12):3230. doi: 10.3390/molecules23123230.
6
Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides.
Bioorg Med Chem Lett. 2017 Dec 1;27(23):5179-5184. doi: 10.1016/j.bmcl.2017.10.053. Epub 2017 Oct 24.
7
Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M positive allosteric modulator (PAM) chemotype via scaffold hopping.
Bioorg Med Chem Lett. 2017 Nov 15;27(22):4999-5001. doi: 10.1016/j.bmcl.2017.10.016. Epub 2017 Oct 9.
8
Discovery of a novel, CNS penetrant M PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core.
Bioorg Med Chem Lett. 2017 Sep 15;27(18):4274-4279. doi: 10.1016/j.bmcl.2017.08.043. Epub 2017 Aug 20.
9
Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.
Bioorg Med Chem Lett. 2017 Jul 1;27(13):2990-2995. doi: 10.1016/j.bmcl.2017.05.014. Epub 2017 May 6.
10
Optimization of M positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2296-2301. doi: 10.1016/j.bmcl.2017.04.043. Epub 2017 Apr 13.
本文引用的文献
1
Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
Neuropsychopharmacology. 2010 Mar;35(4):855-69. doi: 10.1038/npp.2009.194. Epub 2009 Nov 25.
2
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83. doi: 10.1073/pnas.0800567105. Epub 2008 Aug 4.
3
The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?
Psychopharmacology (Berl). 2005 Apr;178(4):451-60. doi: 10.1007/s00213-004-2017-1. Epub 2004 Oct 13.
4
The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis.
J Neurol Neurosurg Psychiatry. 1950 Feb;13(1):47-62. doi: 10.1136/jnnp.13.1.47.
5
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.
Nat Rev Drug Discov. 2004 Apr;3(4):353-9. doi: 10.1038/nrd1346.
6
Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.
Nat Rev Drug Discov. 2002 Mar;1(3):198-210. doi: 10.1038/nrd746.
7
Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice.
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15312-7. doi: 10.1073/pnas.261583798.
8
Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
Schizophr Res. 2000 May 5;42(3):249-59. doi: 10.1016/s0920-9964(99)00138-3.
9
Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10483-8. doi: 10.1073/pnas.96.18.10483.
10
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Arch Neurol. 1997 Apr;54(4):465-73. doi: 10.1001/archneur.1997.00550160091022.
Zotero 插件